[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"altitude\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:altitude":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,55,81,111,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":38,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100638153","study-of-the-effects-of-acute-exposure-to-moderate-altitude-hypoxia-on-prospective-memory-100638153",false,"NCT07585227","Study of the Effects of Acute Exposure to Moderate Altitude Hypoxia on Prospective Memory.","Etude Des Effets d'Une Exposition aiguë à l'Hypoxie d'Altitude modérée Sur la mémoire Prospective (HYPRO)","HYPRO","Inclusion Criteria:\n\n* Healthy volunteer\n* Has provided informed consent\n\nExclusion Criteria:\n\n* Individuals who do not understand French\n* Pregnant or breastfeeding women\n* Cardiovascular risk factor\n* Infectious disease within the last 4 weeks\n* Chronic cardiovascular, respiratory, hematological, neurological, psychiatric, or metabolic disease\n* History of epileptic seizures, convulsions, or loss of consciousness\n* Individuals with migraines\n* History of a bleeding disorder\n* History of high blood pressure\n* Current medication use (excluding contraception)\n* History of episodes of altitude intolerance\n* Stay at high altitude (\\> 3,500 m) within the last 3 months\n* Anxiety score on the Hospital Anxiety and Depression (HAD) scale \\> 7\n* Depression score on the HAD scale \\> 7\n* Uncontrollable claustrophobia or a history of panic attacks",true,"ALL","18 Years","45 Years",{"count":22,"type":23},50,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this study is to investigate whether prospective memory, i.e., memory for delayed intentions, is impaired at moderate altitude (4,000m).\n\nIt will also allow to study the effect of air and oxygen administration during hypoxia exposure.\n\nThe main questions it aims to answer are:\n\n* Does moderate acute hypoxia impair prospective memory ?\n* If so, does air or oxygen adminsitration induce a restoration of prospective memory? Researchers will compare cognitive performance during normobaric hypoxia exposure to cognitive performance during normoxia (control situation).\n\nParticipants will:\n\n* Session S0. Perform a battery of neuropsychological tests and questionnaires). EEG will be recorded during tests. A cheek swab will be performed.\n* Sessions S1 and S2. Perform several cognitive tasks while exposed to hypoxia and to normoxia (2 different sessions, randomized order) in a normobaric chamber. These are standardized cognitive tests administered on a computer and cognitive tests embedded in a flight simulator scenario. Various questionnaires will be performed on a regular basis. Several physiological measurements will be performed continuously: EEG, ECG, SpO2 and breathing rate. Blood pressure will be measured at the beginning and at the end of hypoxia\u002Fnormoxia exposure. A blood sample will also be performed. At last, participants will inhale air or oxygen through a mask while making a cognitive task in the chamber.",[29,30,31,32,33,34,35,36,37],"Hypoxia","Hypoxia Brain","Hypoxia Altitude Simulation Test","Hypoxia in Healthy Individuals","Hypoxia, Altitude","Hypoxia, Brain","Altitude","Altitude Hypoxia","Normobaric Hypoxia",[39,40,41],"prospective memory","working memory","flight simulator","NOT_YET_RECRUITING","2026-05-09",{"date":45,"type":46},"2026-05-13","ACTUAL",{"date":48,"type":23},"2026-05-06",{"date":50,"type":23},"2026-12-31",{"name":52,"class":53},"Direction Centrale du Service de Santé des Armées","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":54},"100627579","field-study-on-intravenous-iloprost-for-treatment-of-severe-frostbite-at-high-altitude-100627579","NCT07450469","Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude","High-Altitude Iloprost Feasibility Study for Treatment of Frostbite","HAI-Frost","Inclusion Criteria:\n\n* Frostbite grade 3\u002F4 eligible for Iloprost\n* \\\u003C72h of thawing\n* min. age of 18 years\n* provision of written informed consent\n\nExclusion Criteria:\n\n* age \\\u003C18 years\n* general contraindication\n* pregnancy\n* inability\u002Fdenial to provide informed consent",{"count":64,"type":23},10,"OBSERVATIONAL","The goal of this observational study is to learn whether intravenous iloprost treatment for severe frostbite (grades 3-4) is feasible and safe when delivered in pre-hospital, remote high-altitude settings.\n\nThe main questions it aims to answer are:\n\n* Is it feasible to initiate and deliver guideline-based intravenous iloprost for grade 3-4 frostbite at high altitude and what logistical barriers arise?\n* Does field-based initiation of iloprost increase tissue preservation and reduce amputations (compared to historical cases from similar settings)?\n\nParticipants receiving Iloprost as part of a frostbite treatment will be followed up after discharge as well as 6, 12 and 18 months to assess tissue preservation and long-term sequelae from the initial frostbite injury.",[68,35,69],"Frostbite","Field Physician Care",[71],"iloprost","2026-03-05",{"date":74,"type":46},"2026-03-09",{"date":76,"type":23},"2026-05",{"date":78,"type":23},"2028-05",{"name":80,"class":53},"Institute of Mountain Emergency Medicine",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":89,"targetDuration":4,"studyType":24,"phases":91,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":54},"100603905","determination-of-iron-absorption-and-losses-in-people-living-at-high-altitude-to-investigate-the-requirements-in-this-population-group-using-a-newly-developed-technique-100603905","NCT07142590","Determination of Iron Absorption and Losses in People Living at High Altitude to Investigate the Requirements in This Population Group Using a Newly Developed Technique","Iron Balance in Humans Living at High Altitude: Defining Requirements and Optimal Biomarker Thresholds Using a Novel Body Iron Labelling Technique Based on Stable Iron Isotopes.","ARIA","Inclusion Criteria:\n\n* Females and males aged 18-45 y\n* BMI: 18 to 25 kg\u002Fm2\n* Body weight \\\u003C70 kg for females, \\\u003C85 kg for males\n* Plasma ferritin \\>25 µg\u002FL\n* Signed informed consent\n\nExclusion Criteria:\n\n* Hb \\\u003C12 g\u002FdL (females), Hb \\\u003C13 g\u002FdL (males), corrected for altitude using the 2024 WHO guidance values for hemoglobin adjustments\n* Inflammation (CRP \\> 5 mg\u002FL)1\n* Plasma ferritin \\>150 µg\u002FL for females and \\>200 µg\u002FL for males\n* Chronic disease known to affect iron metabolism\n* Chronic medications (except for oral contraceptives)\n* Pregnancy (tested at screening) or intention to become pregnant during the course of the study\n* Lactation\n* High physical activity (MET-min\u002Fweek \\> 3000 calculated according to the IPAQ, short version, administered at the screening)\n* Difficulty with blood withdrawal\n* Earlier participation in a study using stable iron isotopes or participation in any clinical study within the last 30 days\n* Smoking\n* Blood donation, blood transfusion or significant blood loss (more than 400 mL) over the past 6 months\n* Intention to regularly donate blood during the 2 years duration of the study\n* No residence in the respective location\u002Faltitude for at least the last 2 years\n* No intention to reside in the respective location\u002Faltitude at least for the next 2 years\n* Participants who are planning to spend an extended period (\\>12 weeks) at a different altitude from their residence location\n* Spending more than 2 nights per week at a different location from residence location\n* Inability to understand the information sheet and the informed consent form due to cognitive or language reasons",{"count":90,"type":23},120,[26],"Iron is an essential micronutrient responsible for a whealth of biological processes of the human body. Iron plays a fundamental role especially in oxygen transport, by binding to hemoglobin in the blood circulation. Iron intake from the diet needs to be in balance the unavoidable losses that occur daily via different pathways. The recommended daily requirement of iron is based on the balance between absorption and losses and is calculated to maintain a balance so that the absorption equals losses. At higher altitudes, the absorption of iron may be higher due to adaptation mechanisms in response to low oxygen concentration, and to maintain a larger erytroid compartement. However, the long-term effects of altitude on iron balance are unknown. Filling this knowledge gap is important to better understand iron deficiency in populations living at high and moderate altitudes. Therefore, the investigators plan to study people that live at two different altitudes and measure iron absorption and losses over the long term. This will be useful to formulate specific recommendations for this population groups, to expand the knowledge base to better prevent iron deficiency in Switzerland but also worldwide. Participants will be asked to consume a dose of stable iron isotopes. After one year from isotope administration, the isotopes will be equally distributed in all body compartments and any change in the isotope abundance with the normal occurring body iron can be detected. From this point onwards, the investigators can observe the iron turnover and calculate iron absorption and losses per unit of time. At 4 different visits blood samples will be taken from each participant.",[94,95,35],"Iron Absorption","Iron Requirements",[97,98,99,100],"iron absorption","altitude","stable iron isotopes","long-term iron balance","RECRUITING","2026-01-13",{"date":104,"type":46},"2026-01-14",{"date":106,"type":46},"2025-08-22",{"date":108,"type":23},"2028-02",{"name":110,"class":53},"Diego Moretti",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":17,"sex":118,"minAge":19,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":54},"100586196","hypoxia-appetite-and-energy-intake-in-young-female-adults-100586196","NCT06912230","Hypoxia, Appetite, and Energy Intake in Young Female Adults","Appetite and Energy Intake in Young Female Adults During and After Simulated High-Altitude","Inclusion Criteria:\n\n* English or French speaking\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* History or evidence of chronic disease\n* Current use of hypolipemic medication\n* Current use of hormonal contraceptives\n* Current use of antidepressants\n* Current use of anticoagulants\n* Ongoing smoking status\n* Experiencing pregnancy, puerperium, or irregular menstrual cycles","FEMALE","30 Years",{"count":64,"type":23},[26],"The goal of this clinical trial is to investigate the effects of acute passive continuous hypoxemia (simulated high-altitude at rest) on appetite and energy intake in healthy young female adults. The main questions it aims to answer are:\n\n* Does six hours of simulated high-altitude (5000 meters) reduce scores of subjective appetite and energy intake?\n* Do changes in appetite and energy intake persist in the hours following the end of hypoxic exposure? Researchers will compare the effects of simulated high-altitude to a control normoxia (sea-level) condition to see if exposure to low oxygen levels independently affect appetite and energy intake.\n\nParticipants will:\n\n* Visit the laboratory for a preliminary screening session to assess eligibility.\n* Undergo two randomized, single-blind, experimental sessions consisting of six hours of passive exposure to normoxia or hypoxia in a climate-controlled chamber.\n* Consume foods provided from a curated list, served in ad libitum quantities, after leaving the laboratory to assess post-exposure energy intake.",[29,35,124,125],"Appetite","Energy Intake","2025-03-28",{"date":128,"type":46},"2025-04-04",{"date":130,"type":46},"2024-11-13",{"date":132,"type":23},"2025-12",{"name":134,"class":53},"University of Ottawa",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":24,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":54},"100584837","short-term-exposure-to-high-altitude-in-patients-with-asymptomatic-aortic-stenosis-100584837","NCT06894550","Short-term Exposure to High Altitude in Patients With Asymptomatic Aortic Stenosis","ASALT","Inclusion Criteria:\n\nGroup 1:\n\n* Moderate or severe aortic stenosis (aortic valve area (AVA) ≤1.5 cm2)\n* NYHA class I\n* LVEF \\> 50%\n* Aortic stenosis staging classification Stage 0 or 1\n* Written informed consent\n\nGroup 2:\n\n* Aortic stenosis s\u002Fp aortic valve replacement within 1 year\n* NYHA class I\n* LVEF \\> 50%\n* Aortic stenosis staging classification Stage 0 or 1\n* Written informed consent\n\nGroup 3:\n\n* NYHA class I\n* LVEF \\>50%\n* No evidence of valvular heart disease\n* Age \\> 65 years\n* Written informed consent\n\nExclusion Criteria:\n\n* NYHA class \\> I (all groups)\n* History of cardiac decompensation requiring hospitalization (all groups)\n* Uncontrolled arterial hypertension (\\>180\u002F100 mmHg at rest) (all groups)\n* Other Cardiomyopathies w\u002F normal LVEF (dilatative, hypertrophic, infiltrative CMP) (all groups)\n* Signs of exercise-induced ischemia (ST-segment depression \\> 2 mV), hemodynamic instability (drop in systolic blood pressure \\> 20 mmHg and systolic blood pressure ≤ 100 mmHg), or ventricular arrhythmias (\\> 5 beats) during cardiopulmonary stress exercise testing (CPET) at Bern (540 meters) (all groups)\n* Chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) \\\u003C60% of the predicted (all groups)\n* Known pulmonary hypertension with a pulmonary artery systolic pressure \\>50 mmHg or high probability of pulmonary hypertension as assessed in TTE (all groups)\n* NT-pro BNP levels \\> 900 pg\u002Fml (all groups)\n* Aortic stenosis staging classification \\> Stage 1 (group 1 and 2)\n* History of advanced stages of acute mountain sickness defined as high altitude pulmonary (HAPE) or cerebral (HACE) edema (all groups)\n* Transvalvular gradient across the aortic valve ≥60 mmHg, Vmax \\>5 m\u002Fs (group 1)\n* Vmax progression ≥0.3 m\u002Fs\u002Fyear (group 1)\n* Transvalvular gradient across the aortic valve ≥20 mmHg (group 2)\n* Evidence of valvular heart disease or coronary artery disease (group 3)\n* History of rhythm disturbances (other than premature ventricular contraction (PVC) (group 3)\n* Right ventricular dysfunction, defined as TAPSE \\\u003C 17 mm, s'DTI \\\u003C 9 cm\u002Fsec (all groups)",{"count":143,"type":23},60,[26],"Aortic stenosis is a common disease with increasing prevalence due to an aging population. Aortic valve replacement is indicated for symptomatic severe aortic stenosis. Leisure activities and tourism at high altitude destinations are popular but may impose a higher risk to patients with aortic stenosis. Pathophysiological considerations led to an expert consensus to avoid high altitude exposure, though there is no robust scientific evidence.\n\nHence, the objective of this study is to evaluate the safety of high altitude exposure in patients with asymptomatic moderate or severe aortic stenosis by the measurement of surrogate markers for cardiac adverse events such as the decrease in exercise capacity, the assessment of changes in cardiac filling pressures, cardiac dimensions and function, and the evaluation of the incidence of cardiac arrhythmia.",[147,35],"Aortic Stenosis",[149,150],"Aortic stenosis","High altitude","2025-03-18",{"date":153,"type":46},"2025-03-25",{"date":155,"type":23},"2025-04-01",{"date":157,"type":23},"2026-09-01",{"name":159,"class":53},"Insel Gruppe AG, University Hospital Bern"]